Gregory Bowles

Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023.

Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023.

Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023.

Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023.

Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023.